Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
08. November 2019 08:00 ET
|
Selecta Biosciences, Inc.
- Compelling preclinical data presented at the European Society of Gene and Cell Therapy Annual Congress demonstrates the potential for redosing in AAV-mediated gene therapy; announced strategic...
Selecta Biosciences Announces Date of Third Quarter 2019 Financial Results Conference Call
01. November 2019 08:09 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting
24. Oktober 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress
23. Oktober 2019 10:48 ET
|
Selecta Biosciences, Inc.
Highlights the ability to prevent formation of vector-induced neutralizing antibodies (Nabs) and enable re-administration of AAV vectors in combination with Selecta’s ImmTOR (SVP-Rapamycin)...
Selecta Biosciences to Participate in Two Investor Conferences in October
25. September 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Appoints Brad Dahms as Chief Financial Officer
04. September 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at the Janney Healthcare Conference
03. September 2019 08:07 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08. August 2019 08:00 ET
|
Selecta Biosciences, Inc.
- New strategic partnership with gene therapy leader, AskBio, to jointly develop next-generation AAV-based gene therapies to address the unmet medical need for repeat dosing in patients with rare and...
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic Partnership
07. August 2019 07:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced a...
Selecta Biosciences Announces Date of Second Quarter 2019 Financial Results Conference Call
01. August 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...